中文摘要：

目的 探讨短发夹RNA／MDR1（shRNA／MDR1）干扰技术能否体内逆转肝细胞癌多药耐药。方法 建立肝细胞癌耐药细胞株HepG2／MDR1和敏感细胞株HepG2裸鼠移植瘤模型，分腹腔注射组和瘤体内注射组，以表达载体pSUPER-shRNA／MDR1转染，阴性对照组以阴性载体pSUPER转染，72h后行腹腔内阿霉素化疗试验，每周2次，共2周，然后处死动物，测量化疗前后肿瘤体积差，瘤体制成细胞悬液和组织切片，分别以流式细胞术和免疫组织化学检测细胞膜P-gp表达。结果 成瘤率100％，HepG2／MDR1组和HepG2组成瘤时间和化疗前肿瘤体积差异无统计学意义，HepG2／MDR1组化疗前后肿瘤体积差（mm^3）与阴性对照组比较差异有统计学意义（700．14±25．611比1659．70±152．54，P〈0．01）；腹腔注射组和瘤内注射组差异无统计学意义。流式细胞术检测发现治疗组细胞膜蛋白P-gp表达率（％）较阴性对照组明显下调（65.1％比94．1％，P〈0．05），腹腔注射组和瘤内注射组差异无统计学意义（94．1％比92.8％，P〉0.05）。瘤体组织病理切片和免疫组织化学分析也有同样的结果。结论 表达载体pSUPER-shRNA／MDR1体内转染可以逆转肝细胞癌多药耐药。

英文摘要：

Objective To explore the possibility of reversal of multidrug resistance of HepG2/ MDR1 by shRNA/MDR1 in vivo. Methods The implant tumors of nude mice were established by injection of cells HepG2/MDR1 and HepG2. Tumors in HepG2/MDR1 were divided into in situ injection groups and intraperitoneal injection groups and were transfeeted by pSUPER-shRNA/MDR1. Negative groups were transfeeted by pSUPER-shRNA/MDR1 negative vectors. Seventy-two h after transfeetion, adriamyein was injected into peritoneal cavity twice a week for two weeks. Tumors were collected by executing the mice to make cell suspension and histological sections for detecting the expression of P-glyeoprotein （P-gp） by flow cytometry and immunohistochemistry. Results The tmnorigenic rate was 100%. There was no difference in tumorigenic time and tumor volume before-chemotherapy between HepG2/MDR1 and HepG2. Compared to negative controls,the increase of tumor volume after chemotherapy in HepG2/MDR1 was slower （ 1659.70 ± 152.54 vs 700.14 ±25.61 ,P 〈 0.01 ）. The expression of P-gp in HepG2/MDR1 was lower than that of negative controls （ 65.1% vs 94.1%, P 〈 0.05 ）. There was no difference between in situ injection groups and intraperitoneal injection groups. Similar results were found by immunohistochemistry. Conclusion The multidrug resistance of HepG2/MDR1 could be reversed by shRNA/MDR1 in v/vo.